Camrelizumab Combined With CD30 CAR-T in the Treatment of Relapsed/Refractory CD30+ Lymphoma
Status:
Recruiting
Trial end date:
2024-06-30
Target enrollment:
Participant gender:
Summary
The is a phase II, single-arm, open-label clinical study assessing the efficacy and safety of
Camrelizumab combined with CD30 CAR-T in the treatment of r/r CD30+ lymphoma. Plan to recruit
30 subjects with r/r CD30+ lymphoma。
Phase:
Phase 2
Details
Lead Sponsor:
Huazhong University of Science and Technology
Collaborator:
The First Affiliated Hospital of Nanchang University